Mineralys Therapeutics (MLYS) Return on Capital Employed (2023 - 2026)
Mineralys Therapeutics (MLYS) reported Return on Capital Employed of 26.69% for Q1 2026, up 4877.0% on a YoY basis from 0.54% in Q1 2025, and up 3.68% sequentially from 27.71% in Q4 2025.
Mineralys Therapeutics (MLYS) Return on Capital Employed (2023 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 4 years of Return on Capital Employed data on file, last reported at 26.69% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 4877.0% year-over-year to 26.69%; the trailing twelve-month figure through Mar 2026 stood at 26.69% (up 4877.0% YoY), and the FY2025 full-year result was 40.74%, up 4911.0% from the prior year.
- Return on Capital Employed advanced to 26.69% in Q1 2026, from 27.71% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 16.44% in Q2 2023 to a low of 86.5% in Q4 2024.
- A 4-year average of 43.11% and a median of 37.5% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 5319 bps in 2024 and surged 5879 bps in 2025, its largest moves.
- Tracing MLYS's Return on Capital Employed over 4 years: stood at 33.31% in 2023, then slumped by 160 bps to 86.5% in 2024, then soared by 68 bps to 27.71% in 2025, then rose by 4 bps to 26.69% in 2026.
- Business Quant data shows MLYS's Return on Capital Employed at 26.69% in Q1 2026, 27.71% in Q4 2025, and 41.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | -26.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.69% |
| Dec 31, 2025 | -27.71% |
| Sep 30, 2025 | -41.43% |
| Jun 30, 2025 | -62.84% |
| Mar 31, 2025 | -75.45% |
| Dec 31, 2024 | -86.50% |
| Sep 30, 2024 | -64.24% |
| Jun 30, 2024 | -44.18% |
| Mar 31, 2024 | -37.50% |
| Dec 31, 2023 | -33.31% |
| Sep 30, 2023 | -24.72% |
| Jun 30, 2023 | -16.44% |
| Mar 31, 2023 | -19.44% |